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Introduction  
Structure of the Paper 
This paper presents a data mining analysis of World Health Organization  
drug adverse event case reports, to examine age-related differences in liver event  
reporting in children, adults and the elderly. These reporting differences were then  
compared to established aging-related physiologic differences, and drug-specific  
physicochemical characteristics to generate hypotheses on hepatotoxicity mechanisms  
which might affect a targeted age group.  
The paper includes three parts: 1. an introduction to the analytic approach, 2. a 
research paper in manuscript form (as a planned submission to Pharmacoepidemiology 
and Drug Safety), and 3. leadership reflections.  
Analytic Approach 
 Over the past 15 years, international regulatory and pharmacovigilance  
experts have tested and established preferred data mining tools and uses in   
publicly available global drug safety datasets (Almenoff 2005).  Data mining uses  
Bayesian and empirical Bayesian methods to adjust for variability in event  
reports, even with small numbers. Disproportionality analyses then identify drug- 
adverse event pairs with unexpectedly high reporting as a potential “signal”,  
using empirically tested thresholds.  Current data mining analyses frequently use the  
high specificity disproportionality-based signal detection method of empirical Bayes  
multi-item gamma Poisson shrinker (MGPS), which provides a quantitative measure of  
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“expectedness” to drug adverse event reports (Almenoff 2006). This quantitative “signal  
score” is then further analyzed with medical case review, disease biology, drug  
interactions and other factors and provides the theoretical foundation for future  
investigations to assess the biologic plausibility of a causal relationship of the drug- 
adverse event pair.  
 With small adverse event counts, MGPS precision is diminished, so the program 
decreases the observed to expected ratios to minimize false-positive signals. The 
MGPS software generally stratifies data by event categories, with 40 year-, 11 age 
group-, and 3 gender-categories (male, female and unknown) to further adjust 
background differences in relative reporting. This adjustment decreases potential 
confounding by variability in prescribing practice and associations with a stratum 
variable. After Bayesian smoothing, empiric Bayes geometric mean (EBGM) values 
demonstrate the strength of the association of the drug and the adverse event pair to 
display the relative reporting rates.  An EBGM of 5 indicates that the drug-adverse event 
combination is reported at a 5-fold higher frequency than expected reporting frequency 
computed assuming that there is no association between the drug and the adverse 
event. Empirically, an EBGM >2 for a drug-adverse event combination is interpreted as 
a significantly increased reporting frequency (a positive association between the drug 
and the adverse event), while an EBGM ≤1 is interpreted as either no association or a 
negative association between the drug and the adverse event. The 90% confidence 
intervals [lower limit (EB05) and upper limit (EB95)] are calculated to assess differences 
in reporting frequency. To examine reporting differences, the EB05 and EB95 intervals 
are compared for an overlap, as performed in the current study. Stratification enables 
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analyses of data subsets, including age groups, over time.   
Data mining is particularly useful for generating hypotheses, which must be 
further tested using alternate data sources, including careful medical case review, 
clinical or epidemiological observational studies, and in-vitro or in-vivo experiments.  
Data mining’s key strength is its ability to sort a large number of drug-adverse event 
pairs and provide a numeric score of how frequently event pairs are observed, relative 
to that which is expected in the database background.  
It’s easy to interpret the results, as the magnitude of this signal score shows the 
strength of the association with confidence limits or p-values. The shortcomings of 
safety data mining are the likely underreporting of adverse events in global safety 
databases, potential reporting biases, and data incompleteness (even for serious or 
fatal events). Causality cannot be inferred with data mining analyses, even when using 
data mining methodology of high specificity. At minimum, additional medical review and 
assessment of biologic plausibility is needed. Therefore, even data mining analyses with 
a high signal score are reported using terms, such as “observed reporting relationship” 
and “possible causality” (Almenoff 2005).  
 Data mining is now routinely performed in drug safety (Rivkees 2010). FDA 
examines global datasets to identify drug adverse event associations between drugs of 
similar structure, indication, or of similar structure and differing indications to generate 
hypotheses about potential new drug adverse events (Almenoff 2006). New “signals” 
are then interrogated through careful medical review. The current study has examined 
new liver safety “signals” by age group, to compare with drug physicochemical 
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properties and aging-specific differences in physiology, to generate hypotheses on the 
mechanisms contributing to drug toxicity susceptibility with development and aging.  
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Abstract (254 words, 250 words = max for Pharmacoepid & Drug Safety) 
Background/aims: Children, adults and the elderly exhibit differing frequency and 
manifestations of drug-induced liver injury, which may be due to physiological changes 
associated with development and/or aging. WHO Safety Report Database data-mining 
analyses assessed the impact of age on liver event reporting frequency with different 
phenotypes.  
Methods: 236 drugs associated with hepatotoxicity in the WHO Safety Report 
Database were evaluated using the Empirical Bayes Geometric Mean (EBGM) of the 
relative reporting ratio with 90% confidence interval (EB05 and EB95) calculated for 3 
different age groups, 0-17, 18-64, and >65 years (or elderly), for overall, serious (acute 
liver failure), hepatocellular, and cholestatic liver injury.  
Results: Overall, cases of age 0-17, 18-64, and 65 years or older comprised 6%, 62%, 
and 32% of liver event reports. Acute liver failure and hepatocellular injury were more 
frequently reported among children compared to adults and the elderly while reports 
with cholestatic injury were more frequent among the elderly (p<0.00001). Twenty-nine 
drugs, including anti-retrovirals, CNS agents, and antimetabolites, were associated with 
significantly higher reporting frequency among children vs. others, while 10 drugs were 
associated with significantly higher reporting frequency among the elderly. Regarding 
drug characteristics, a potential to cause mitochondrial dysfunction was more prevalent 
among the drugs with increased pediatric reporting frequency while high lipophilicity and 
biliary excretion were more common among the drugs associated with higher reporting 
frequency in the elderly.  
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Conclusion: Our analysis identified age-specific phenotypes in reported liver events 
and potential drug properties associated with age-specific hepatotoxicity. Further 
analyses are warranted to better understand potential age-specific susceptibility.  
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Introduction  
In the United States, drug-induced liver injury is the leading cause of death from 
acute liver failure in adults (Ostapowitz 2002). Older adults (age 60 and over) exhibit 
generally similar outcomes to younger adults (Schiødt 2009). In contrast, children with 
drug-induced acute liver failure can exhibit much poorer outcomes than adults, with a 
73% one year mortality after liver transplantation for antiepileptic-induced liver failure 
(Mindikoglu 2009). Fortunately, children rarely exhibit drug-induced acute liver failure, 
which accounts for only 20% of acute liver failure events (Murray 2008), and is primarily 
associated with acetaminophen, anti-epileptics and anti-tuberculosis drugs (Squires 
2006, Molleston 2011). While children (<18 years) comprise 26% of the US population, 
they account for only 7% of reported serious drug adverse events overall (Moore 2007), 
with hepatic events accounting for only 1% of reported pediatric adverse drug events 
globally (Ferrajolo 2010).  
Overall, serious drug adverse events account for 3-6% of hospital admissions 
(Moore 2007). The average ambulatory Medicare patient consumes 4 medications or 
more daily (Gurwitz 2003), and most (63%) use complementary and alternative 
medications (Cheung 2007), contributing to adverse drug reactions (Gurwitz 2003). 
While the elderly (>65 years) constitute only 13% of the US population (Moore 2007), 
they account for approximately one third of serious adverse drug reports. The US 
elderly population is growing rapidly and will double by 2050 (US Census Bureau), so 
identifying and addressing risk factors for drug-induced liver injury in this vulnerable 
population is a key concern.   
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Nearly half (46%) of drug-induced liver injury events in the large, prospective 
Spanish Drug-induced Liver Injury Registry occurred in those over age 60, with 
amoxicillin/clavulanate frequently implicated. Amoxicillin/clavulanate is the most 
common cause of drug-induced liver injury in many countries, accounting for 
approximately 10% of cases (Andrade 2005, Chalasani 2008) and up to 57% of cases 
of antibiotic-induced jaundice (Hussaini 2007). The incidence of drug-induced liver injury 
with amoxicillin/clavulanate increases 3-fold with age, multiple prescriptions, longer 
treatment duration (Garcia Rodriguez 1996) and specific HLA Class I and II alleles 
(Lucena 2011), with cholestatic injury most common in the elderly (Lucena 2009).  
Most drugs (77%) causing drug-induced liver injury or acute liver failure are 
administered at daily doses of 50 mg or higher (Lucena 2009) and undergo significant 
hepatic metabolism (Lammert 2010). Furthermore, 85% or more of drugs with both a 
high daily dose (>100 mg) and high lipophilicity (with octanol-water partition coefficient, 
or logP > 3) are significantly associated with hepatotoxicity (Chen 2013).   
Age and development substantially influence drug metabolism (Kearns 2003, 
Klotz 2009), inflammation and regeneration (Hohensinner 2011, Grolleau-Julius 2010, 
Chen 2010). Children exhibit age-related changes in drug absorption, distribution, 
metabolism and excretion, which are most marked in infancy and are generally similar 
to adults in children over age 8 (Kearns 2003). Mitochondrial DNA polymerase gamma 
gene (POLG1) polymorphisms frequently manifest in the first few years of life and 
contribute to valproate hepatotoxicity (McFarland 2008, Squires 2006). When 
coadministered with other anti-epileptics, valproate hepatotoxicity results in a 1 in 550 
rate of acute liver failure in those under age 2 (Murray 2008), in contrast to 1 in 80,000 
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rate of significant hepatotoxicity in adults (Dealberto 2007). Children may be more 
susceptible to medications causing mitochondrial injury and hepatotoxicity, in 
comparison to adults and the elderly.  
Liver mass, regeneration, and hepatic blood flow decrease with normal aging, 
resulting in lower first pass clearance of select drugs in the elderly (Klotz 2009, 
Schmucker 2011), although the activity of most Phase I and II enzymes are unaffected 
by aging (Klotz 2009, Hunt 1990, Hunt 1992, Schwartz 2006, Schmucker 2011). 
However, inter-individual pharmacokinetic variability can increase due to aging-related 
changes in drug disposition in the elderly with increasing body fat or delayed gastric 
emptying, decreased renal blood flow and excretion (Klotz 2009), and decreased 
mitochondrial function (Lo´pez-Lluch 2008).  A moderate decline in biliary function, with 
decreased bile flow and bile acid secretion, and in liver regeneration following injury is 
observed in the elderly (Schmucker 2011). Aging-related relative immune deficiencies 
and increased autoimmunity are associated with shortening telomeres, increasing 
CD28- T cells contributing to auto-reactivity, DNA hypomethylation, and alterations in 
histone acetylation (Hohensinner 2011, Grolleau-Julius 2010). Drugs of high lipophilicity 
or exhibiting high first pass clearance, or those undergoing biliary excretion or resulting 
in autoimmune injury, may more commonly result in hepatotoxicity in the elderly, due to 
the aforementioned aging-related physiologic changes.  
It’s essential to examine the effect of aging on drug-induced liver injury 
manifestation and frequency in children and the elderly to avoid the risk of severe and 
unpredictable injury in these vulnerable populations. Drug-induced liver injury occurs 
infrequently (Sgro 2002, de Abajo 2004), so large databases are needed to examine 
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risk factors. The World Health Organization (WHO) Safety Report Database is a global 
database of adverse drug reactions that includes millions of reports (Lindquist 2008). To 
assess the impact of age on liver event reporting frequency and phenotype, two 
hundred thirty six drugs associated with hepatotoxicity were evaluated with data-mining 
analyses in the WHO Safety Report Database. Drugs associated with a higher reporting 
frequency by age group were further analyzed by physicochemical properties, daily 
dose, metabolism, transport, immunologic, or other attributes or liabilities by age group. 
We hypothesized that mitochondrial dysfunction could be more common in drugs 
associated with pediatric hepatotoxicity (due to inborn mitochondrial genetic defects), 
and that drugs of highly lipophilicity, dose, high first pass clearance, biliary excretion, or 
which inhibit bile acid efflux (e.g. through the bile salt export pump or multidrug 
resistance associated proteins -2, -3, and -4) could be more highly represented in the 
elderly.  The findings of this data-mining analysis further refined the theoretical 
foundation for future investigations on aging-related susceptibilities to hepatotoxicity.  
Identification of aging-related susceptibilities to targeted drug properties will in turn help 
to avoid or minimize these features in the design of new drugs for these age groups. In 
addition, the identification of specific drugs associated with hepatotoxicity in targeted 
age group will enable clinicians to select safer alternatives.      
Methods 
Study Design:  This is a descriptive data mining analysis using a large global data set 
from a spontaneous adverse event reporting system to assess the effect of age on 
reporting frequency of drug-associated liver injury with different clinical phenotypes. 
This study used only coded data provided in the released version of the WHO Safety 
! 14!
Report VigiBase™ database without accessing identifiable private information and was 
reviewed by the University of North Carolina Office of Human Research Ethics, which 
determined that this study does not constitute human subjects research as defined 
under federal regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)] and does 
not require IRB approval.  
Data Source: The WHO global individual case safety report (ICSR) VigiBase™ 
database is broadly utilized in pharmacovigilance and drug-induced liver injury research 
(Suzuki 2010). VigiBase™ (1968-2013) is the world’s largest spontaneous adverse 
event reporting system, with more than 6 million case reports from 104 countries; it 
includes both regulatory and voluntary sources (Lindquist 2008).  The VigiBase™ data 
set released in the third quarter of 2012 was used.  
Reporting frequency of liver events: Disproportionality of reporting frequency ratios 
for a drug-liver event pair in VigiBase™ were determined, relative to all other drugs and 
events in the database (relative reporting ratio). Applying Bayesian statistics, the 
relative reporting frequency of liver events was converted to the Empirical Bayes 
Geometric Mean (EBGM) of the relative reporting ratio with a 90% confidence interval 
(CI) (EB05 and EB95) using Empirica™ Signal (Oracle Corporation, Redwood Shores, 
CA) for 3 different age groups: children (0-17 years), adults (18-64 years), and the 
elderly (65 years or older). Liver-related cases were excluded if no age information was 
available. EBGM and 90%CI were computed using 4 custom liver events terms to 
address reporting frequency of liver events with different phenotypes.  
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The 4 custom liver event terms were created, combining groups of ‘Preferred Terms’ 
(codes from the Medical Dictionary for Regulatory Activity, MedDRA): hepatocellular 
injury, cholestatic injury, acute liver failure and a combined overall term (which includes 
the prior three groups). Lists of ‘Preferred terms,’ used to define these custom terms, 
are summarized in Supplementary Table 1. As shown in the Supplementary Table 1, 
the ‘Preferred Terms’ used to define hepatocellular injury, cholestatic injury, and acute 
liver failure were not mutually exclusive, had some overlap among the three groups, and 
percentages were calculated using the total numbers of the reported liver events as 
denominators.   
Study drugs: Two hundred thirty six drugs were evaluated in this study. Of the 385 
drugs previously reported to be associated with hepatotoxicity (Drug Safety, 2010), 236 
drugs were: 1) reported in the VigiBase™ with liver event related codes and 2) 
associated with an increased reporting frequency of liver events (defined as an EBGM 
equal to or greater than 2), which formed the data set for our analysis.  
Drugs selectively affecting age groups:  For the 236 drugs evaluated in this study, 
we compared reporting frequency of liver events among different age groups as detailed 
in the statistical analysis section and explored drugs which were associated with an 
increased reporting frequency of liver events in specific age groups. The identified drugs 
were further analyzed by: daily dose; lipophilicity, as measured by octanol-water 
partition coefficient (logP) (Chen 2013); plasma half-life; transporter interactions 
(Dawson 2012, Thompson 2012, Morgan 2013); metabolism (DailyMed), metabolism 
dependent inhibition, production of reactive metabolites or glutathione adducts (Sakatis 
2012); mitochondrial impairment (in vitro or in vivo) (Pessayre 2012, Thompson 2012); 
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genetic polymorphisms associated with hepatotoxicity or altered metabolism (Daly 
2012, Russman 2010); age-related differences in clearance; biliary excretion, 
hypersensitivity or other attributes or liabilities by age group. To assure data 
completeness, drug lipophilicity, daily dose, mitochondrial effects, transporter 
interactions, biliary excretion and hypersensitivity were searched in PubMed and/or 
Google Scholar. A Google search was completed for drugs missing lipophilicity 
information alone. Product labels (DailyMed) were the primary source of data, followed 
by the published literature, for: plasma half-life, metabolism, aging-related differences in 
drug clearance, HLA-associated toxicity, production of reactive metabolites, glutathione 
adducts, protein covalent binding and metabolism dependent inhibition. !
Statistical analyses: The results were reported in a descriptive manner. Total numbers 
of reported liver events were calculated for the 236 drugs using the combined overall 
liver event term. To compare frequency of liver events with different clinical phenotypes 
among the different age groups, we used Chi-square tests. To compare reporting 
frequency of liver events among the age groups, 90% CI of EBGM (EB05, EB95) using 
the combined overall liver term were compared among the groups. For instance, to 
identify drugs associated with an increased reporting frequency of liver events among 
children, drugs in which the EB05 for children were higher than EB95s for others (e.g. 
adults and elderly adults) were selected. Drugs associated with an increased reporting 
frequency of liver events among the elderly were selected by EB05 for the elderly higher 
than EB95 for others (e.g. children and non-elderly adults). Fisher’s exact test was used 
to compare targeted drug characteristics of the 29 drugs with higher reporting in the 
children (relative to all other age groups) to the 10 drugs with higher reporting in the 
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elderly (relative to all other age groups). Specifically, the proportion of drugs associated 
with high daily drug dose, lipophilicity, mitochondrial dysfunction, biliary excretion and 
bile salt export pump (BSEP) inhibition were compared between the two drug groups 
using Fisher’s exact tests. Other drug characteristics, which were associated with 
significant missing information, were not statistically analyzed. 
Statistical analyses were performed using JMP statistical software version 9.0 (SAS 
Institute Inc., Cary, NC) and STATA version 12.1 (StataCorp LP, College Station, 
Texas), and differences were considered statistically significant when the p-value(s) 
were less than 0.05.  P-values have not been adjusted for multiple comparisons due to 
exploratory nature of the analyses.    
 
Results  
A total of 1,813,187 reported cases were related to the 236 drugs;  150,782 
cases (9%) were liver-related. Sixteen percent of these liver-related cases were missing 
age information and were excluded from the analysis, leaving 126,875 cases for 
evaluation.  
Children were associated with a higher reporting frequency of acute liver failure 
(12%) compared to adults (8%) and the elderly (6%) (P<0.00001, Chi-square test) while 
the elderly were associated with a higher reporting frequency of cholestatic injury events 
(33%) compared to adults (27%) and children (22%) (P<0.00001, Chi-square test) 
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(Table 1). Most (62%, n=78514) liver event reports were in adults age 18-64, while 32% 
(n=40560) were 65 years or older and only 6% (N=7801) were age 0-17 (Table 1). 
When comparing the reporting frequency of liver events among the age groups, 
10 drugs were associated with a significantly higher reporting frequency of liver events 
among the elderly, including:  antibiotics (amoxicillin/clavulanate, flucloxacillin, fusidic 
acid, roxithromycin, and combination therapy with isoniazid, pyrazinamide and rifampin), 
steroids (cyproterone and danazol), and others (chlorpromazine, carbimazole, and 
nimesulide) (Table 2).  
On the other hand, relative to adults and the elderly, 29 drugs were associated 
with a significantly higher reporting frequency of liver events in children including:  anti-
retrovirals (abacavir, indinavir, ritonavir, and zidovudine), CNS agents (pemoline and 
valproic acid), antimetabolites (methotrexate and mercaptopurine), and antibiotics 
(oxacillin and minocycline) (Table 3).    
Characteristics of drugs associated with hepatotoxicity which differ among 
elderly and children 
 Drug characteristics were examined for the identified 39 drugs to assess 
potential associations with differing reporting frequency by age group (Table 4). A high 
daily dose (>100 mg) was present in the large majority of the identified drugs (87%), 
which was significantly higher than reported prevalence (<32%) of this daily dose 
among the 230 drugs most commonly used in the US (p<0.0001) (Lammert 2008).   
Regarding physicochemical drug properties, drugs associated with a higher 
pediatric reporting frequency had a tendency to be associated with mitochondrial 
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dysfunction compared to drugs associated with a higher reporting frequency in the 
elderly (58.6% vs. 20%, p=0.06). On the other hand, drugs associated with a higher 
reporting frequency in the elderly tended to exhibit higher lipophilicity (as defined by 
logP equal or greater than 3), when compared to drugs associated with a higher 
pediatric reporting frequency (50% vs. 21%).  Although not statistically significant, biliary 
excretion and bile salt export pump (BSEP) inhibition were more commonly reported 
with drugs associated with a higher reporting frequency in the elderly than the children 
(70% vs. 44.8%, 30% vs. 13.8%, respectively). Reactive metabolites, and glutathione 
(GSH) adducts were more commonly observed with drugs associated with a higher 
reporting frequency in the elderly, while covalent binding was more frequent with drugs 
associated with a higher pediatric reporting frequency, although these data were 
missing for many drugs. No apparent differences were noted between the two drug 
groups in reported hypersensitivity, metabolism dependent inhibition (MDI), or impact on 
multidrug resistance associated proteins -2, -3, and -4 (MRP-2, 3, 4). Across age 
groups, most drugs underwent hepatic metabolism; however, metabolism was 
incompletely defined for 41% (16/39) of drugs. Increased drug exposure or decreased 
clearance with aging were reported in 4 of 10 drugs with higher reporting in the elderly, 
in comparison to 1 of 29 drugs with higher reporting in children, although age-related 
differences in clearance were not assessed for some of these 29 drugs.     
Discussion 
In the global VigiBaseTM dataset, phenotype-specific differences in reporting 
frequency of liver events were evident among different age groups: with more acute 
liver failure reporting among children and more cholestatic injury (with less 
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hepatocellular injury) reporting among the elderly. Drug specific differences in the 
reporting frequency were also apparent among the age groups. Children exhibited a 
higher reporting frequency of liver events, relative to all other ages, associated with 29 
drugs including CNS agents (e.g., valproic acid, pemoline), anti-retrovirals (3 protease 
inhibitors and 3 nucleoside reverse transcriptase inhibitors), antimetabolites (e.g., 
methotrexate) and antibiotics (e.g., minocycline).  In contrast, the elderly exhibited an 
increased liver event reporting, relative to the other age groups, for 10 drugs, mainly 
antibiotics, including amoxicillin/ clavulanate and flucloxacillin.   
Age-specific frequency, phenotypes, and outcomes of drug-induced liver injury are 
not yet fully characterized. Using the Spanish Drug-Induced Liver Injury registry, Lucena 
et al (2009) reported that older age is associated with cholestatic injury and younger 
age with hepatocellular damage. This observation is consistent with our findings of the 
reporting frequency data in the VigiBase.TM Furthermore, previous case-series studies 
using pediatric populations reported a predominance of hepatocellular injury. Although 
the true incidence of drug-induced liver injury cannot be addressed based on the 
reporting frequency of liver events in a spontaneous adverse event reporting system, 
these currently available data suggest that age may influence manifestations of drug-
induced liver injury.  
In our study, the 39 drugs in which reporting frequency was associated with specific 
age groups (29 drugs among children and 10 drugs among the elderly), were further 
examined for their chemical, physical, and pharmacological characteristics and 
compared between the groups (the 29 vs. 10 drugs). Half of the drugs with higher 
reporting in the elderly combined both high daily dose and high lipophilicity, in 
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comparison to a small minority of those in children. This potential susceptibility to highly 
lipophilic drugs in the elderly may be related to increasing body fat with aging, altering 
drug disposition, and/or different intracellular distribution. Biliary excretion and bile salt 
export pump (BSEP) inhibition were more common in drugs with higher reporting in the 
elderly versus children, which combined with the aging-related decrement in biliary 
function (Schmucker 2011, Morgan 2013), may contribute to the higher rate of 
cholestatic liver disease in the elderly. Few drugs associated with higher reporting in the 
elderly or children had HLA polymorphisms associated with hepatotoxicity (Table 4). 
Among the 29 drugs with higher liver event reporting in children, more than half are 
associated with mitochondrial dysfunction, in contrast to few in the elderly. Most 
compounds were associated with hypersensitivity. If confirmed, these drug-specific 
findings can be applied to the clinic and to drug development, to minimize the use of 
drugs resulting in mitochondrial impairment in children and drugs with high lipophilicity,  
biliary excretion, or BSEP inhibition in the elderly.    
In a comparison of hepatotoxicity to first-line anti-tuberculosis drugs, adjusted for 
compliance, approximately 1 per 1000 children vs 31 per 1000 adults (> 55 years) 
exhibited hepatotoxicity (Forget 2006). Generally, an increased risk of hepatotoxicity 
with antituberculosis therapy is associated with genetic polymorphisms (N-
acetyltransferase 2 slow acetylators, CYP2E1 c1/c1 wild type, glutathione S-transferase 
M1 null, and manganese superoxide dismutase mutant C allele) (Huang 2012), older 
adults, and with malnutrition, alcohol abuse, viral hepatitis B or C, or HIV infection 
(Murray 2008). However, despite the relatively high frequency of liver injury with 
antituberculosis therapy, most patients develop adaptation due to initiation of 
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antioxidant defenses and liver regeneration, and liver injury resolves (Pessayre 2012). 
However, liver regeneration declines with normal aging (Schmucker 2011), which may 
contribute to the aging-related increase in liver injury due to antituberculosis therapy. In 
this study, although we observed an increased reporting frequency of liver events 
related to first-line anti-tuberculosis drugs in the elderly, reporting frequency of individual 
anti-tuberculosis drugs were higher in children. Reasons for this discrepancy are 
uncertain.  
The strengths of this study include its use of the global VigiBaseTM with over 6 million 
drug safety reports over decades, which span all ages and marketed drugs. The large 
dataset provided sufficient cases to stratify data across age categories of interest. Drug 
properties were identified which were associated with age-specific liver event reporting. 
Potential mechanisms of age-specific susceptibilities were highlighted by comparing 
these results to nonclinical, physiologic, and epidemiologic studies, including drug-
induced liver injury registries. 
This study is limited by it’s use of the WHO VigiBase;TM  this database includes 
largely voluntarily reported adverse events from health care providers, patients, and 
regulators. While some countries mandate adverse drug reporting, US reporting is 
voluntary and yields most of the adverse drug reports in VigiBase.TM The two major 
issues of this database include: 1) under-reporting of events and 2) incompleteness or 
inaccuracy of reported data. Providers are not reimbursed or rewarded for reporting 
adverse drug events, so less than 10% of events are reported; many events are 
reported with incomplete, or inaccurately recalled, information. Furthermore, a reporting 
bias can arise with publicity about a suspect drug adverse drug reaction resulting in 
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transiently increased reporting. For example, while propylthiouracil has been marketed 
for 60 years, liver injury event reports in children increased 10-fold between 1983-2003, 
with severe liver injury and death most frequent in children (Rivkees 2010). This finding 
resulted in “Dear Practitioner” letters warning of this suspect adverse drug reaction, 
announcements to Endocrine societies, and publications, and further increased 
reporting through 2008 (Rivkees 2010). To estimate the proportion of reporting related 
to publicity, one can determine if reporting has declined in followup years. Symptomatic 
drug-induced liver injury is rare and frequently misdiagnosed. Yet, drug: liver event 
reporting can increase due to co-existing disease without a true causal association. For 
example, congestive heart failure in the elderly may contribute to over-reporting of 
cholestatic liver disease. Additionally, unreliable high signal scores can result from small 
numbers of events, which typically decrease as additional data accrues. Therefore, a 
high disproportionality score does not necessarily indicate either a causal association of 
the drug and the liver event, or even a high incidence of liver injury.  High signal scores 
can arise from background disease in the population using the suspect drug, publicity 
about suspect drug adverse drug reactions resulting in a reporting bias, concomitant 
medicines frequently paired with the suspect drug, or differences in drug dosing or 
frequency. Hence, this WHO data generates hypotheses regarding potential causal 
associations between drugs and events, to be further examined in prospective drug-
induced liver injury registries, epidemiology studies and clinical research.  Another 
limitation of the WHO VigiBaseTM is that exact drug dosage, the frequency and duration 
of drug usage, and chronological relationship of drugs with events are unknown, so the 
liver injury incidence cannot be assessed. Nevertheless, these analyses raise refined 
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research questions about age-related toxicity differences, which can be further 
evaluated to optimize drug safety and monitoring in children and the elderly.  
In summary, our data-mining analysis addressed age-related differences in reporting 
of drug-associated liver injury and provided refined theories for future investigations 
related to age-specific susceptibilities. Likely due to inborn mitochondrial defects, higher 
reporting was observed in children with drugs associated with mitochondrial impairment: 
CNS agents, anti-retrovirals, antimetabolites and antibiotics. With age-related declines 
in biliary function and liver regeneration, higher reporting in the elderly appeared in 
highly lipophilic drugs with biliary excretion. An enhanced understanding of age-related 
differences in hepatotoxicity will help to identify and address mechanisms of injury, and 
improve patient safety. With confirmation, these findings can inform clinicians and drug 
development to minimize use of drugs resulting in mitochondrial impairment in children 
and highly lipophilic drugs in the elderly.    
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Table 1. Overall frequency of WHO liver event reporting by age group 
 
Liver Event Type Children 
(Age 0-17)  
Adults 
(Age 18-64) 
Elderly  
(Age > 65) 
Cholestatic injury* 22% 27% 33% 
Hepatocellular injury* 82% 81% 77% 
Acute liver failure* 12% 8%  6% 
Total N of cases 7801 78514 40560 
*not mutually exclusive 
Total numbers of WHO reported liver events were calculated using the combined overall term for the 236 drugs.   
The classification of different clinical phenotypes, hepatocellular injury, cholestatic injury, and acute liver failure, was not 
mutually exclusive and percentages were calculated using the total numbers of the reported liver events as denominators. 
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Table 2. Drugs associated with significantly higher WHO liver event reporting frequency among the elderly  
Generic Name  
N of drug-specific reports N of drug-specific liver reports EBGM 
Children Adults Elderly Children Adults Elderly Children Adults Elderly 
Amoxicillin and 
Clavulanate* 
7241 23559 12517 190 2608 2218 1.5 3.0 4.6 
Carbimazole 142 2789 1563 1 246 207 0.4 2.4 3.3 
Chlorpromazine 741 9871 2197 52 979 373 2.5 2.3 3.9 
Cyproterone 58 800 1271 4 81 347 1.9 2.6 5.7 
Danazol 43 2699 337 2 181 64 1.3 1.8 4.4 
Flucloxacillin 1087 4153 2845 67 957 972 2.9 5.4 7.9 
Fusidic Acid 476 1492 1294 38 217 378 3.8 3.5 7.0 
Isoniazid And 
Pyrazinamide And 
Rifampicin 
57 830 372 9 243 147 4.5 7.2 10.0 
Nimesulide 227 3542 1244 6 367 210 1.2 3.1 4.8 
Roxithromycin 875 4306 1646 28 306 170 1.5 1.9 2.5 
*pooled 
Total numbers of WHO drug-specific reports and drug-specific liver reports for drugs among the 236 drugs associated 
with hepatotoxicity which showed a significantly higher reporting frequency in the elderly (age 65 or greater).  A higher 
EBGM score indicates a greater strength of association of the liver event with the drug. 
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Table 3. Drugs associated with significantly higher WHO liver event reporting frequency among children 
Generic Name  
N of drug-specific reports N of drug-specific liver reports EBGM 
Children Adults Elderly Children Adults Elderly Children Adults Elderly 
Abacavir 237 4899 158 32 443 14 6.6 2.1 2.0 
Allopurinol 568 20542 29098 58 1462 1632 4.2 1.7 1.5 
Amiodarone 269 8706 23412 28 670 1687 4.6 1.8 1.9 
Atorvastatin 466 41827 42089 30 2581 2414 3.8 1.7 1.8 
Bosentan 281 3123 2391 66 856 644 12.4 8.6 9.0 
Carbamazepine 7615 35448 9859 591 2658 847 3.1 1.9 2.1 
Codeine And 
Paracetamol 745 16607 9348 37 772 403 1.9 1.2 1.1 
Dapsone 236 3216 504 34 397 64 5.3 3.0 3.1 
Didanosine 541 7678 172 60 1016 22 6.1 3.0 2.7 
Ethambutol 650 9698 3108 164 1930 756 12.1 5.1 6.3 
Fluconazole 1324 15134 4583 157 1543 467 6.2 2.7 2.8 
Hydrocodone & 
Paracetamol 351 20816 6541 24 915 225 2.7 1.4 1.1 
Indinavir 208 7100 158 27 646 9 5.1 1.9 1.2 
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Generic Name  
N of drug-specific reports N of drug-specific liver reports EBGM 
Children Adults Elderly Children Adults Elderly Children Adults Elderly 
Isoniazid 1282 14247 4070 319 3047 1109 9.7 5.3 6.7 
Josamycin 359 445 151 32 41 16 4.2 2.2 1.9 
Mercaptopurine 1291 1982 296 150 230 38 5.4 3.3 3.3 
Methotrexate 5077 34548 16732 509 1843 552 4.8 1.6 1.0 
Minocycline 1881 6855 892 213 597 68 3.4 2.3 1.9 
Nelfinavir 460 3732 99 39 356 2 5.4 2.3 0.7 
Oxacillin 630 1167 503 65 96 45 5.0 1.9 2.0 
Paracetamol 30153 89224 45379 1139 6521 2718 2.3 2.0 1.7 
Pemoline 724 703 67 216 90 3 9.2 3.0 1.0 
Propylthiouracil 177 2246 588 35 242 42 7.4 3.1 1.7 
Pyrazinamide 571 8167 2134 159 2004 713 13.6 6.5 8.6 
Rifampicin 1324 13488 5240 326 2978 1451 12.1 5.6 7.1 
Ritonavir 465 8357 247 87 1012 24 10.0 2.9 2.4 
Sulfasalazine 533 10449 3621 54 1014 245 3.4 2.5 1.7 
Valproic Acid 11667 39623 6638 1084 2444 451 4.1 1.6 1.8 
Zidovudine 1817 12872 234 160 917 12 6.4 1.8 1.2 
Total numbers of WHO drug-specific reports and drug-specific liver reports for drugs among the 236 drugs associated 
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with hepatotoxicity which showed a significantly higher reporting frequency in children (age 0 to 17). A higher EBGM score 
indicates a greater strength of association of the liver event with the drug. 
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Table 4. Characteristics of drugs with higher WHO liver event reporting frequency in children or the elderly 
 
Drug 
Daily 
dose  logP 
Plasma 
t1/2 (hrs) BSEP MRP  
Biliary 
excr 
Mito 
dysftn HLA 
Hyper-
sens 
React 
metab 
GSH 
adduct 
Coval 
bindg MDI 
High child report 
frequency                           
Abacavir12,16,69 600 0.8 1.5 0 0 0 1 1 1 1 0 0 0 
Allopurinol12,16,79,95 400 -1.5 1 0 0 1 0 0 1 0 0 0 0 
Amiodarone12,16,60,68,69,79 200 7.2       36-58 0 0 1 1 0 1 0 0 0 1 
Atorvastatin16,22,60,79       10-80 4.53 14 1 1 1 1 0 0 0 0 1 0 
Bosentan12,16,18 250 3.9 5 1 0 1 0 0 1 0 0 0 0 
Carbamazepine12,16,69,79,89 1000 2.7       12-65 0 0 1 0 1 1 1 1 1 0 
Codeine & paracet-
amol12,16,69,79,89  3000 0.7       1.2-3 0 1 0 1 0 0 0 1 1 0 
Dapsone12,16,18,69 50 1.4 28 0 0 0 0 0 0 1 0 0 0 
Didanosine12,16,69 400 -0.8 1.2 0 0 0 1 0 0 0 0 0 0 
Ethambutol12,16,72 1200 0.1           2-4 0 0 0 0 1 1 0 0 0 0 
Fluconazole12,16 200 0.75 30 0 0 0 0 0 0 0 0 0 1 
Hydrocodone & para-
cetamol12,16,69,79,89,96 3000 0.7     1.3-3.8 0 1 0 1 0 0 0 1 1 0 
Indinavir4,12,16,57,60 2400 3.1 1.8 0 0 1 1 0 1 0 0 0 1 
Isoniazid12,15,16,66,69,77 300 -0.8 2.8 0 0 0 1 1 0 1 0 0 0 
Josamycin10,16,25,27,62,87 500 1.24 
 
0 0 1 1 0 1 0 0 0 0 
Mercaptopurine12,16,68,88 200 0.4 1 0 1 0 1 0 1 0 0 0 0 
Methotrexate12,16,18,69 2.5 0.1         3-15 0 0 1 1 0 1 0 0 0 0 
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Drug 
Daily 
dose  logP 
Plasma 
t1/2 (hrs) BSEP MRP  
Biliary 
excr 
Mito 
dysftn HLA 
Hyper-
sens 
React 
metab 
GSH 
adduct 
Coval 
bindg MDI 
High child report 
frequency                           
Minocycline12,16,69 200 0.4       11-22 0 0 0 1 0 1 0 0 0 0 
Nelfinavir4,16,57,60 2500 4.46        3.5-5 0 0 1 1 0 1 0 0 0 1 
Oxacillin16,63,94,95 2000 1.9 0.5 0 0 1 0 0 1 0 0 0 0 
Paracetamol12,16,69,79,89,96 3000 0.7        1.2-3 0 1 0 1 0 0 0 1 1 0 
Pemoline12,16,54 40 1.3 12 0 0 0 0 0 1 0 0 0 0 
Propylthiouracil12,16,41,69,95 100 1.6 
 
0 0 1 0 0 1 1 0 0 0 
Pyrazinamide12,16,69 1500 -1        9-10 0 0 0 0 0 1 0 0 0 0 
Rifampicin12,16,18,60,69,77 600 1.4 
 
1 0 1 0 1 1 0 0 0 0 
Ritonavir12,16,57,60,89 1200 4.9 
 
1 1 1 0 0 1 0 0 1 1 
Sulfasalazine12,16,39 2000 2      10-15 0 1 0 1 0 1 0 0 0 0 
Valproic Acid12,16,18,69,79 1500 2.7       9-16 0 0 0 1 0 1 1 0 1 0 
Zidovudine4,12,16,68,69,79 600 0.1      0.5-3 0 1 0 1 0 1 0 0 0 0 
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Drug 
Daily 
dose  logP 
Plasma 
t1/2 
(hrs) BSEP MRP  
Biliary 
excr 
Mito 
dysftn HLA 
Hyper-
sens 
React 
metab 
GSH 
adduct 
Coval 
bindg MDI 
Higher reports in elderly                           
Amoxicillin:clavu- 
lanate10,16,22,60.79 500 0.97      1-1.3 0 0 0 0 1 1 0 1 0 0 
Carbimazole10,16,23,53,67,79         5-20 1.26 
 
0 0 1 0 0 1 0 1 0 1 
Chlorpromazine12,18,33,66, 69,95 100 4.7 
 
0 0 1 0 0 1 1 0 0 0 
Cyproterone10,16,44,53,69   200-300 3.41     45-95  0 0 0 0 0 0 1 0 0 0 
Danazol12,16,60 600 4.9     10-24  1 0 1 0 0 0 0 0 0 0 
Flucloxacillin1,10,16,17,53,60, 
69,90,95 1000 2.57 
 
0 0 1 0 1 0 1 1 0 0 
Fusidic 
acid7,10,16,17,53,60,69,90,95 1500 5.7   1 1 1 0 0 1 0 0 0 0 
INH+Pyrazin.+ Rifampin12,15-
18,,66,69,77 300 -0.8     2.8-10  1 0 1 1 1 1 1 0 0 0 
Nimesulide6,12,16,78,92 200 2.2    1.8-4.7 0 1 0 1 0 0 1 0 1 0 
Roxithromycin10,14,16,40,71,95 300 3.07 10 0 0 1 0 0 1 0 0 0 0 
 
*clearance decreased in the elderly 
Drug characteristics were summarized for those drugs with higher relative WHO liver event reporting in children, age 0-17 (portrayed in upper table) or the elderly 
(age 65 or higher). Profiled characteristics included daily drug dose, logP (or lipophilicity; where logP>3 is associated with high lipophilicity and increased risk of 
toxicity), and drug plasma half-life in hours. Drug interaction with bile salt export pump (BSEP) or multidrug resistance associated proteins (MRP-2, -3, and -4), 
biliary excretion, mitochondrial dysfunction, HLA marker(s) associated with toxicity, hypersensitivity, reactive metabolites, glutathione (GSH) adducts, covalent 
binding, or metabolism dependent inhibition (MDI) are presented as detected=1 or absent or unknown=0. The following categories were associated with missing 
data:  HLA-associated toxicity, production of reactive metabolites, glutathione adducts, protein covalent binding and metabolism dependent inhibition. 
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Supplementary Table 1.  
 
Liver Injury Type Custom Preferred Search Terms 
Hepatocellular injury 
 
 'Acute hepatic failure', 'Alanine aminotransferase abnormal', 'Alanine aminotransferase  
increased', 'Aspartate aminotransferase abnormal', 'Aspartate aminotransferase increased',  
'Blood bilirubin unconjugated increased', 'Cytolytic hepatitis', 'Hepatic enzyme abnormal',  
'Hepatic enzyme increased', 'Hepatic failure', 'Hepatic function abnormal', 'Hepatic necrosis',  
'Hepatitis', 'Hepatitis acute', 'Hepatitis fulminant', 'Hepatitis toxic', 'Hepatocellular damage', 
'Hepatotoxicity', 'Jaundice hepatocellular', 'Liver function test abnormal', 'Liver injury',  
'Mixed hepatocellular-cholestatic injury', 'Subacute hepatic failure', 'Transaminases abnormal',  
'Transaminases increased' 
Cholestatic Injury 
  
'Mixed hepatocellular-cholestatic injury', 'Bilirubin conjugated increased', 'Bilirubin urine',  
'Blood bilirubin abnormal', 'Blood bilirubin increased', 'Cholestasis', 'Hepatitis cholestatic',  
'Hyperbilirubinaemia', 'Jaundice', 'Jaundice cholestatic', 'Urine bilirubin increased', 'Yellow skin' 
Hepatic failure 
 
‘Coma hepatic', 'Hepatic encephalopathy', 'Hepatic failure', 'Hepatic necrosis', 'Hepatitis fulminant',  
'Liver transplant' 
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Reflection on how leadership learnings helped to impact the study problems 
 The key leadership values, which helped me to address the study problems, 
include passion for my work, teamwork with highly motivated collaborators, shared 
goals and vision, respect and affection for my diverse team members, and 
empowerment of team members. I have had the privilege of working with our high-
performing project team members on prior drug safety projects. With our team’s deep 
expertise in epidemiology, data mining, statistics, and liver injury, my vision was to seek 
unifying mechanisms of aging-related toxicity differences, which could inform clinicians, 
regulators, and drug developers.  
My key leadership strengths are strategic vision, or ability to “see the big picture”, 
innovative ideas, flexible persistence, and ability to engage others in rapid change (as 
indicated by my strong originator scores on the Change Style Indicator Test, and the 
Gallup Organization’s Strength Finders 2.0).  Through testing more than a million 
people, the Gallup Organization’s survey reliably identifies a person’s top 5 strengths. 
Then, through maximizing your strengths, you can enjoy greater success and pleasure 
in your work. My strengths align with my personality type as an extrovert, intuitive, 
thinker, and judge (on Myers-Briggs Type Indicator). As most people do not seek 
change or new ideas, I have frequently found myself impatiently waiting for others to 
“see” the value and scope of new ideas, to realize our shared vision.   
I now recognize that I can partner with other talented people with similar focus to 
achieve our goals, by enabling each team member to work to their strengths.  As 
demonstrated in the evidence-based data of Jim Collins’ Good to Great, truly great 
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teamwork happens when you get talented, disciplined, diverse people working together 
towards an inspiring goal.  By letting people innovate together, freely sharing ideas and 
capitalizing on their talents, you can achieve anything.  I’ve had the great pleasure to 
work with high-performing team members who are self-motivated innovators, with whom 
I’ve established trust and respect, to rapidly achieve results (as accomplished in this 
project). In broader groups, I’ve also realized that presenting ideas and strategies in a 
more detailed fashion assures that diverse colleagues all understand and can thereby 
further contribute to our team ideas. So, I’ve worked to be more deliberate in my 
reasoning, which is of particular value when sharing ideas and results outside our team.   
To ensure public health success, there’s a pressing need to develop women 
leaders and expand leadership diversity. So, I brought together productive female 
colleagues with diverse talents to discuss the issue, our resources, and each person’s 
level of interest in the project. We agreed that pediatric data were very limited. Heide 
Stirnadel is an epidemiologist with a longstanding interest in hepatotoxicity, having 
collaborated with the CDC on the toxicity of anti-tuberculosis medications. Heide 
identified clinical study data in over 9000 children, which would be of high value to 
understand pediatric safety. She expressed a keen interest in examining this data, and 
was somewhat hindered by limited resource. So, we identified interested statistical 
colleagues, discussed with FDA and EU regulators to confirm a high level of regulatory 
interest, and I met with Heide’s management to share the high value of this research. 
Our collaborative input enabled Heide’s analysis. I nominated Heide to share her data at 
an FDA national meeting, where she gave an excellent presentation and met with senior 
academicians and FDA colleagues to advance her work.  
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Ayako Suzuki’s a highly creative translational physician scientist of international 
renown, with deep expertise in hepatology, epidemiology and statistics. Nancy Yuen’s a 
talented drug safety expert, data miner and pharmacist. Together, Ayako and Nancy 
have developed innovative data mining approaches to examine large datasets to 
develop new hypotheses. I recognized that their unique expertise would greatly expand 
our understanding of drug toxicity with aging, and nicely complement Heide’s 
epidemiology and toxicity expertise. So, I asked their interest in collaborating on drug 
toxicity with aging. I personally contributed my passion for patient safety, curiosity in 
understanding liver injury, and resolve to achieve our goal.   
Our mutual respect, work ethic, friendship, and interests have made Ayako, 
Nancy, Heide and I successful long-term collaborators. Together, we were united by a 
clear common goal, maximized our quite different skills to develop a protocol, complete 
the data mining analysis, and achieve a high quality product. Our team of women is 
diverse & productive:  age 30-50’s, of differing backgrounds, personalities, expertise, 
career stage, and approaches.   
In my team leadership, I’ve encouraged a broad range of views and approaches 
with emphasis on innovation, a high level of respect of all team members, good listening 
skills, evidence-based assessment, excellence in execution, and emphasized 
recognition of team members for their contributions. I’ve enjoyed mentoring, and 
empowering team members to lead analyses and studies in their area of expertise, 
which has resulted in their career advancement and broad global opportunities and 
collaborations for our team.  
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My future leadership goals include collaboratively developing automated 
diagnostic tools using electronic health records with global colleagues and building 
automated clinician-friendly systems for health prevention activities in US health 
systems. These goals will enable me to use my key strengths:  collaborative leadership, 
strategic vision and ideas. Simultaneously, I seek to achieve my goal of becoming an 
excellent public health leader, which I define as a leader who innovates to improve 
health broadly, shares and adapts their vision to unite others in productive 
collaborations to achieve their mutual goal, is energizing and catalyzes new ideas, 
communicates and listens well, encourages questions and reasoned conflict, inspires 
others to excellence, seeks team diversity and challenge, applauds team members’ 
efforts and progress, supports team members in their personal development and goals, 
and creates a fun and engaging environment where all can excel. 
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